Dispose of the used syringe immediately in a sharps container
Box 1: Recent Trump Administration Obesity Drug Initiatives In November 2025, the Trump administration announced reaching a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1s for Medicare, Medicaid, and those purchasing the drugs directly from the manufacturers through a new TrumpRx website
Semaglutide works well, but it may not work well enough for individuals with severe metabolic dysfunction or those seeking outcomes beyond simple appetite reduction
Note: If youre already receiving a GLP-1 through Medicare Part D for an FDA-approved covered usesuch as diabetes, cardiovascular disease, MASH, or obstructive sleep apneayoull continue getting that medication through your Part D plan
You are still on the starting dose The 2mg starting dose produces minimal appetite effects for most people
Even patients who stayed on GLP-1 medications for a full year lost significantly less weight than surgical patients